Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

67.57 +0.49 (+0.73%)
Streaming Delayed Price Updated: 12:53 PM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PTC Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
PTC Therapeutics Crashes 29% After European Regulators Reject Its Muscular Dystrophy Drug
The company is working on a treatment for Duchenne muscular dystrophy. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases
Treating rare diseases is a tough but potentially lucrative business. With clinical trials coming due, here are three stocks to buy. 
Via InvestorPlace
Where PTC Therapeutics Stands With Analysts
 
Via Benzinga
Raymond James Maintains Outperform Rating for PTC Therapeutics: Here's What You Need To Know
 
Via Benzinga
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
Where PTC Therapeutics Stands With Analysts
 
Via Benzinga
Morgan Stanley Maintains Equal-Weight Rating for PTC Therapeutics: Here's What You Need To Know
 
Via Benzinga
What 15 Analyst Ratings Have To Say About PTC Therapeutics
 
Via Benzinga
14 Analysts Have This to Say About PTC Therapeutics
 
Via Benzinga
PTC Therapeutics' Seizure Study Fails To Meet Primary Goal, Analyst Says Minimal Impact On Investment Thesis
PTC Therapeutics Inc (NASDAQ: PTCT) said its MIT-E trial of vatiquinone for mitochondrial disease-associated seizures (MDAS) failed to achieve its primary endpoint of  
Via Benzinga
PTC Therapeutics Says Interim Data For Huntington's Disease Candidate Shows Promise In Mid-Stage Study
PTC Therapeutics Inc (NASDAQ: PTCT) shared interim data from the 12-week portion of the PIVOT-HD Phase 2 study of PTC518 in  
Via Benzinga
3 High-Potential Small-Cap Stocks for Investors With Strong Stomachs
Small-cap stocks can be risky, and all three of these companies are facing adversity. But they could be home run investments. 
Via InvestorPlace
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against PTC Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
The Latest Analyst Ratings for PTC Therapeutics
 
Via Benzinga
Why America's Car-Mart Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares jumped 209.1% to $0.5622 after the United States Patent and Trademark Office granted the company a patent for certain medical systems and methods. 
Via Benzinga
PTC Therapeutics Stock Tumbles: Company Stops Preclinical Gene Therapy Programs After Failed Friedreich's Ataxia Study
 
Via Benzinga
Dow Falls Over 100 Points; Analog Devices Posts Upbeat Q2 Earnings
U.S. stocks traded lower this morning, with the Dow Jones dropping over 100 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.44% to 32,908.94 while the NASDAQ fell... 
Via Benzinga
Why Is Apexigen (APGN) Stock Up 31% Today?
Apexigen (APGN) stock is rising higher on Wednesday following news of a $16 million acquisition deal with Pyxis Oncology (PYXS). 
Via InvestorPlace
Why Is Ocugen (OCGN) Stock Down 22% Today?
Ocugen (OCGN) stock is falling on Wednesday after the pharmaceutical company revealed details of a public offering for its shares. 
Via InvestorPlace
Why Is PTC Therapeutics (PTCT) Stock Down 21% Today?
PTC Therapeutics (PTCT) stock is taking a beating on Wednesday after the company provided investors with an update on a clinical trial. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Inovio Pharmaceuticals Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares rose 202.3% to $0.5499 in pre-market trading. Minerva Surgical was granted U.S. Patent #11653972 for "Medical Systems And Methods (For Resecting And... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for a dive into the biggest pre-market stock movers as we check out all of the latest news for Wednesday morning! 
Via InvestorPlace
Agilent, PTC Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against PTC Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
PTC Therapeutics Takes Investors On A Ride With A Failed Study, Scrapped Programs, Ousted CFO
PTC announced a barrage of news, starting with a failed Phase 3 study. 
Via Investor's Business Daily
Chart Of The Day: PTC Therapeutics
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for patients with rare disorders. 
Via Talk Markets
Palo Alto Networks To Rally Around 21%? Here Are 10 Other Analyst Forecasts For Thursday
Needham raised the price target for Dynatrace, Inc. (NYSE: DT) from $52 to $56. Needham analyst James Ricchiuti maintained a Buy rating. Dynatrace shares gained 1.9% to $47.95 in pre-market trading. 
Via Benzinga
Why PTC Therapeutics Could Be Victorious In Its Rare-Disease Battle Against BioMarin Pharmaceuticals
The company is working on a treatment for PKU, a disorder that can lead to intellectual disabilities. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.